5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval
FDA Approves Subcutaneous Tocilizumab for Ages 2–17
FDA Rejects Novartis Bid to Repurpose Inflammation Drug for Heart Attacks
Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
FDA Expands Safety Measures for Immediate Release Opioids
FDA Issues Safety Warning
EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval
- 1
- 2
- 3
- 4
- Next Page »